Sep 16, 2019
SillaJen Defending Position Relating to Recent Sale of Stock by Employee
Aug 02, 2019
SillaJen Announces Conclusions From Interim Futility Analysis Of Phase 3 PHOCUS Trial in HCC
Jun 06, 2019
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)
Mar 26, 2019
BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
Jan 09, 2019
Oncolytic Virus Cancer Therapy Pipeline Insights Report 2018: Some of the Emerging Products include Pexa-Vec of Transgene/SillaJen, Telomelsin of Oncolys, and Canerpaturev (TBI-1401) of Takara Bio
Oct 24, 2018
OncoSec Announces Publication of Data in Nature Gene Therapy Demonstrating the Ability of its Newly Optimized Intratumoral IL-12 Immunotherapy Platform to Increase Systemic Anti-tumor Responses in both Treated and Untreated Lesions
Sep 04, 2018
SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
Jan 29, 2018
SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec Oncolytic Immunotherapy
Jan 22, 2018
SillaJen and ABL Europe Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies
Aug 16, 2017
SillaJen Announces Collaboration with the National Cancer Institute for Development of Combination Therapy with SillaJen's pexastimogene devacirepvec (Pexa-Vec) Oncolytic Immunotherapy
Jul 21, 2017
SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer